Catalyst Wire Dossier Catalyst Wire Dossier

BZE2204 CAR-T cells

CD19/CD22/BCMA CAR-T cells · Shanghai Cell Therapy Group Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BZE2204 CAR-T cells, covering 2025-09-16 to 2025-09-16. Get the full timeline:

Most recent: Clinical Trial Update: An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases [EARLY_Phase 1]

See pricing